TCGA-85-8351-01A-11R-2296-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 72
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.670
- MYC_TARGETS_V1+0.580
- E2F_TARGETS+0.480
- TGF_BETA_SIGNALING+0.480
- G2M_CHECKPOINT+0.460
- UNFOLDED_PROTEIN_RESPONSE+0.430
- MITOTIC_SPINDLE+0.390
- TNFA_SIGNALING_VIA_NFKB+0.390
- ANDROGEN_RESPONSE+0.380
- MTORC1_SIGNALING+0.370
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.390
- BILE_ACID_METABOLISM-0.340
- KRAS_SIGNALING_DN-0.330
- INTERFERON_ALPHA_RESPONSE-0.300
- INTERFERON_GAMMA_RESPONSE-0.280
- ALLOGRAFT_REJECTION-0.230
- HEDGEHOG_SIGNALING-0.220
- XENOBIOTIC_METABOLISM-0.170
- SPERMATOGENESIS-0.150
- OXIDATIVE_PHOSPHORYLATION-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-66-2753-01A-01R-0980-07 | — | cohortSQ1 | 0.860 |
| 2 | BS_9XVACXP0 | high-grade glioma | — | 0.854 |
| 3 | TCGA-56-7222-01A-11R-2045-07 | — | cohortSQ1 | 0.850 |
| 4 | DD5AA3F8-E3EE-4EDD-8152-B1CC07B70A08 | — | — | 0.836 |
| 5 | 98D004A9-E3F0-448E-BFE2-359F25DF356C | — | — | 0.836 |
| 6 | MDT-AP-3285 | Med | Medulloblastoma | 0.831 |
| 7 | ERR2598051 | fetal | fetal | 0.830 |
| 8 | TCGA-H7-8502-01A-11R-2403-07 | — | — | 0.820 |
| 9 | 50DE1FDE-B85E-4677-B0F8-08275DA41A6E | — | — | 0.814 |
| 10 | A3153235-3128-40AC-9371-AFA1F61E3E59 | — | — | 0.812 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.670 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.580 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.480 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.460 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.430 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.390 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.380 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.370 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.230 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.230 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.180 | Inavolisib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |